DU4475 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The DU4475 cell line is a human breast cancer cell line derived from a metastatic site. It is characterized by its aggressive nature and poor differentiation, often used in research to study the mechanisms of cancer metastasis and progression. The cell line has been utilized extensively to explore the therapeutic targets and the efficacy of anti-cancer drugs in treating highly invasive breast cancer types. Genetically, DU4475 exhibits a high level of genetic instability, which is a hallmark of many cancer cells. This feature makes it a valuable model for studying the genetic and molecular events leading to cancer development and progression. Research involving DU4475 often focuses on the pathways that regulate cancer cell growth, survival, and resistance to chemotherapy, making it a critical resource for oncological studies aiming to develop more effective cancer treatments. |
|---|---|
| Organism | Human |
| Tissue | Breast |
| Disease | Breast carcinoma |
| Metastatic site | Skin |
| Applications | 3D cell culture, Immuno-oncology |
| Synonyms | Du4475, DU-4475, Du-4475, DU 4475, Du 4475, Duke University 4475 |
Characteristics
| Age | 62 years |
|---|---|
| Gender | Female |
| Ethnicity | European |
| Morphology | Epithelial |
| Growth properties | Clusters in Suspension |
Regulatory Data
| Citation | DU4475 (Cytion catalog number 300371) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1183 |
Biomolecular Data
| Isoenzymes | AK-1, 1, ES-D, 1, G6PD, B, GLO-I, 2, Me-2, 2, PGM1, 1-2, PGM3, 1 |
|---|---|
| Tumorigenic | Yes, in nude mice |
| Viruses | EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-1/2 -, MLV -, SMRV - |
| Karyotype | Human flat-moded near-tetraploid karyotype with 12% polyploidy - 88-93<4n>xxxx, +1, +1, -5, -6, +9, -10, -10, +15, +15, -16, -16, +22, +4mar, i(1q)x2, ?add(1)(p35-36)x2, ?i(5p)x2, add(6)(p11), add(6)(p1?), del(6)(q25), add(9)(q35), del(11)(q24)x2, add(15)(p11)x2, add(17)(p1?)x2, del(21)(q22.2)x2 - sideline with -20, -20, +del(7)(p11) - gain of 1q and loss of 6q typical in breast carcinoma - resembles published karyotype |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 15% heat-inactivated FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300371-020924 | Certificate of Analysis | 18. Dec. 2025 | 300371 |
| 300371-221223 | Certificate of Analysis | 23. May. 2025 | 300371 |